Skip to main content

Instant redemption funds, UPI payments, KYC and more on the MobiKwik App!

Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Growth

Add To Compare

previously known as Reliance Pharma Gr until

NAV on October 01, 2026
Category Equity:
Sector - Healthcare
Investment StyleBox
Total Assets ₹9,479 cr
Turnover Ratio 13.85%
Expense Ratio 1.84%
Exit Load 1.00%if redeemed within
1 Months
0.00%if redeemed after 1 Months
Returns
  • 1M: Negative return: -3.03%
  • 1Y: Positive return: 11.38%
  • 3M: Positive return: 0.58%
  • 3Y: Positive return: 16.57%
  • 6M: Positive return: 14.39%
  • 5Y: Positive return: 12.50%
Min Investment ₹5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 21 years) Kinjal Desai (Since over 8 years) Amber Singhania (Since 7 months)
ISIN INF204K01968
Fund Family Nippon
P/E Ratio 39.20
P/B Ratio 5.82
Launch Date June 05, 2004
Benchmark BSE Healthcare TR INR

Asset Allocation

  • Equity: 98.0%
  • Debt: 2.0%
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha -2.48
Beta 0.88
R-Squared 94.66
Info Ratio -1.17
Tracking Err 3.96
Sortino 1.125
Sharpe 0.696
Std Dev 15.056
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

View Factsheet

-

Best Sector Healthcare Funds

Name Latest NAV Returns 1y   Fund Assets Expense Ratio Risk
₹ 51.144 20.26% ₹ 3,555 cr 0.61% -
₹ 584.618 20.19% ₹ 5,796 cr 1.04% -
₹ 378.650 16.65% ₹ 1,444 cr 1.26% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon